Who are allogeneic stem cell transplant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, RAK therapy, Autologous platelets rich plasma, IL-2 pre-treated CD19 cells, hUCB, Relma-cel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/allogeneic-stem-cell-transplant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

allogeneic stem cell transplant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

allogeneic stem cell transplant (allogeneic stem cell transplant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Oncology, Hematology, Immunology.

phase 3 Cell therapy Oncology, Hematology, Immunology Biologic Live · refreshed every 30 min

Target snapshot

allogeneic stem cell transplant (allogeneic stem cell transplant) — University of Wuerzburg. Allogeneic stem cell transplant replaces a patient's diseased or damaged bone marrow with healthy stem cells from a donor to restore normal hematopoietic and immune function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
allogeneic stem cell transplant TARGET	allogeneic stem cell transplant	University of Wuerzburg	phase 3	Cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
RAK therapy	RAK therapy	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Cell therapy
Autologous platelets rich plasma	Autologous platelets rich plasma	Mostafa Hassanein, Msc	marketed	Autologous cell therapy / Regenerative medicine product
IL-2 pre-treated CD19 cells	IL-2 pre-treated CD19 cells	jiangjingting	marketed	Adoptive cell therapy	CD19
hUCB	hUCB	StemCyte Taiwan Co., Ltd.	marketed	Allogeneic hematopoietic stem cell therapy
Relma-cel	Relma-cel	Shanghai Ming Ju Biotechnology Co., Ltd.	marketed	CAR-T cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
Bone Therapeutics S.A · 1 drug in this class
DiscGenics, Inc. · 1 drug in this class
Celavie Bioscences, LLC · 1 drug in this class
China Spinal Cord Injury Network · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Brainstorm-Cell Therapeutics · 1 drug in this class
Dr. Grant M. Pagdin · 1 drug in this class
FDA Office of Orphan Products Development · 1 drug in this class
Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). allogeneic stem cell transplant — Competitive Intelligence Brief. https://druglandscape.com/ci/allogeneic-stem-cell-transplant. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing